AbCellera Q2 net loss $36.9M, revenue down 28% YoY; Lilly collaboration expanded

AbCellera Biologics Inc.

2024-Q2 EPS reported -$0.26 revenue$17,277,000

Net loss $36.9M ($0.13/sh) vs $30.5M loss in Q2 2023; revenue $7.3M down from $10.1M.
Partner-initiated program starts 93 cumulative (+16% YoY); molecules in clinic 14 (+56% YoY).
Expanded Lilly collaboration to immunology, CV, neuroscience; Invetx to be acquired by Dechra for up to $520M.
Abdera's ABD-147 received FDA IND clearance and Fast Track; AbCellera holds low-single-digit royalty and mid-single-digit equity.
Cash and securities $697.6M plus ~$220M non-dilutive government funding; total liquidity >$900M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.